P6-Aggrate
P6-Aggrate is a fluorescent probe for aggregated proteome detection. P6-Aggrate specifically recognizes amorphous aggregated proteomes through non-covalent reversible binding, and its fluorescence enhances after heat-induced protein aggregation. P6-Aggrate reflects the polarity and compactness heterogeneity within aggregated proteomes via emission wavelength shift: short-wavelength emission (blue shift) corresponds to large aggregates with high compactness, while long-wavelength emission (red shift) corresponds to small spots with low compactness (Ex/Em = 488/520-580 nm). P6-Aggrate enables reversible monitoring of the dynamic processes of formation and clearance of stress-induced proteome aggregation such as that induced by MG132 (HY-13259) in living cells. P6-Aggrate can be used in studies related to protein homeostasis imbalance, neurodegenerative diseases and protein aggregation.
For research use only. We do not sell to patients.
- Formula: C28H25NO3
- Molecular Weight:423.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Operating Instructions
Operating Instructions (The following is a recommended experimental protocol for guidance only, and adjustments are required based on your specific needs).
1. Stock Solution Preparation
1.1 Solvent: Most dyes are usually dissolved in organic solvents, such as anhydrous DMSO.
1.2 Concentration Recommendation: Prepare a high-concentration stock solution at 1-10 mM.
2. Working Solution Preparation
2.1 Diluent: Serum-free medium or PBS is generally used. Proteins and esterases in serum may interfere with staining results or cause dye hydrolysis.
2.2 Working Concentration: 4-50 μM.
2.3 Notes: Adjust the working solution concentration as needed; prepare and use immediately.
3. Staining Procedure
3.1 Sample Type: Adherent cells (HeLa cells)[1].
3.2 Incubation Conditions: Incubate cells with 5 μM P6 and MG132 (HY-13259) for 24 h; avoid light during confocal imaging.
4. Detection and Analysis
4.1 Instrument: Confocal fluorescence microscope
4.1.1 Excitation wavelength: 488 nm; emission wavelength can be adjusted within the range of 520-580 nm.
4.2 Result Analysis:
4.2.1 Fluorescence intensity change: Fluorescence intensity increases upon binding to amorphous aggregated proteomes; fluorescence intensity decreases and red shift occurs after aggregate clearance.
4.2.2 Fluorescence localization: Localizes to proteome aggregates (which can be small speckle-like particles or large perinuclear aggregates depending on the cell stress status).
4.2.3 Color change: Aggregates show green fluorescence under standard imaging conditions; a shorter emission wavelength (blue shift) indicates higher aggregate compactness, while a longer emission wavelength (red shift) indicates lower aggregate compactness.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Molecular Weight 423.50
-
Formula C28H25NO3
-
SMILES
CC1(C2=CC(N3CCOCC3)=CC=C2C4=C1C=C(C=C4)/C=C5OC6=C(C\5=O)C=CC=C6)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)